Biocartis Group NV, an innovative molecular diagnostics company, today announces the establishment of its US subsidiary, Biocartis US Inc., and the appointment of Vishal Sikri as its US General Manager
Both are important next steps in the execution of Biocartis' US strategy following the announced commercialisation agreement with Thermo Fisher Scientific Inc. in November 2016.
Vishal is a highly experienced executive with a proven global commercial and operational track-record in molecular diagnostics. Before joining Biocartis, he was Managing Director and VP Commercial Operations responsible for all global commercial operations of Sysmex Inostics, the molecular diagnostics' division of Sysmex Corporation. Prior to that, he held various roles within Sysmex America Inc. and Sysmex Corporation, including amongst others the position of Director New Business Development. Before joining Sysmex in January 2007, Vishal held different Senior Product Management roles within Abbott Laboratories. Vishal holds a degree in Pharmaceutical Sciences (University of Wisconsin) and a Master's in Business Administration (Loyola University of Chicago).
Vishal Sikri, General Manager of Biocartis US Inc., commented: "I truly believe that with Idylla, we will make a difference in the US market where there is a pressing need for easy, rapid and highly accurate oncology diagnostic solutions.”
Hilde Windels, Chief Executive Officer of Biocartis, added: "Vishal has been championing commercial growth strategies in molecular diagnostics in oncology for most of his career. With a broad background varying from clinical trial management to sales & marketing, medical affairs, business development and M&A, and a particular expertise in liquid biopsy testing and companion diagnostics, we are confident that Vishal will successfully establish Biocartis in one of the largest molecular diagnostics markets in the world.”
We are confident that Vishal will successfully establish Biocartis in one of the largest molecular diagnostics markets in the world.
Biocartis expects to start commercial roll-out in the US of its rapid and fully automated Idyllavplatform and its accompanying assays, with a first focus on oncology research products, in H2 2017. The Company will open its US office in the New Jersey area.